BioXcel Therapeutics (BTAI) Non-Current Assets (2017 - 2026)

BioXcel Therapeutics' Non-Current Assets history runs 10 years deep, the most recent figure standing at $117000.0 for Q1 2026.

• On a quarterly basis, Non-Current Assets fell 85.17% year-over-year to $117000.0 in Q1 2026; TTM through Mar 2026 was $1.3 million, a 68.61% decrease from a year earlier, with the FY2025 full-year figure at $231000.0, down 75.53% from the prior year.
• Non-Current Assets declined to $117000.0 in Q1 2026 per BTAI's latest filing, from $231000.0 in the prior quarter.
• Across five years, Non-Current Assets topped out at $3.5 million in Q1 2022 and bottomed at $117000.0 in Q1 2026.
• The 5-year median for Non-Current Assets is $1.4 million (2024), against an average of $1.6 million.
• Across the five-year window, Non-Current Assets gained 13.63% in 2022 and sank 85.17% in 2026, its largest moves.
• Year by year, Non-Current Assets stood at $3.0 million in 2022, then sank by 47.77% to $1.6 million in 2023, then slumped by 39.45% to $944000.0 in 2024, then plunged by 75.53% to $231000.0 in 2025, then plunged by 49.35% to $117000.0 in 2026.
• Per Business Quant, the three latest BTAI Non-Current Assets figures stand at $117000.0 (Q1 2026), $231000.0 (Q4 2025), and $389000.0 (Q3 2025).